Yau, ThomasThomasYauPark, Joong-WonJoong-WonParkFinn, Richard SRichard SFinnANN-LII CHENGMathurin, PhilippePhilippeMathurinEdeline, JulienJulienEdelineKudo, MasatoshiMasatoshiKudoHarding, James JJames JHardingMerle, PhilippePhilippeMerleRosmorduc, OlivierOlivierRosmorducWyrwicz, LucjanLucjanWyrwiczSchott, EckartEckartSchottChoo, Su PinSu PinChooKelley, Robin KateRobin KateKelleySieghart, WolfgangWolfgangSieghartAssenat, EricEricAssenatZaucha, RenataRenataZauchaFuruse, JunjiJunjiFuruseAbou-Alfa, Ghassan KGhassan KAbou-AlfaEl-Khoueiry, Anthony BAnthony BEl-KhoueiryMelero, IgnacioIgnacioMeleroBegic, DamirDamirBegicChen, GongGongChenNeely, JaclynJaclynNeelyWisniewski, TamiTamiWisniewskiTschaika, MarinaMarinaTschaikaSangro, BrunoBrunoSangro2023-01-122023-01-122022-0114702045https://scholars.lib.ntu.edu.tw/handle/123456789/627193Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1-2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients with advanced hepatocellular carcinoma.enTHERAPYjournal article10.1016/S1470-2045(21)00604-5349148892-s2.0-85121898359WOS:000821937900041https://api.elsevier.com/content/abstract/scopus_id/85121898359